

Anna Piotrowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3396937/publications.pdf>

Version: 2024-02-01

34
papers

1,347
citations

257429

24
h-index

361001

35
g-index

35
all docs

35
docs citations

35
times ranked

1367
citing authors

#	ARTICLE	IF	CITATIONS
1	Maraviroc reduces neuropathic pain through polarization of microglia and astroglia – Evidence from in vivo and in vitro studies. <i>Neuropharmacology</i> , 2016, 108, 207-219.	4.1	91
2	Targeting the NLRP3 Inflammasome-Related Pathways via Tianeptine Treatment-Suppressed Microglia Polarization to the M1 Phenotype in Lipopolysaccharide-Stimulated Cultures. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1965.	4.1	84
3	Parthenolide Relieves Pain and Promotes M2 Microglia/Macrophage Polarization in Rat Model of Neuropathy. <i>Neural Plasticity</i> , 2015, 2015, 1-15.	2.2	80
4	Blockade of Toll-Like Receptors (TLR2, TLR4) Attenuates Pain and Potentiates Buprenorphine Analgesia in a Rat Neuropathic Pain Model. <i>Neural Plasticity</i> , 2016, 2016, 1-12.	2.2	77
5	Blockade of P2X4 Receptors Inhibits Neuropathic Pain-Related Behavior by Preventing MMP-9 Activation and, Consequently, Proinflammatory Interleukin Release in a Rat Model. <i>Frontiers in Pharmacology</i> , 2017, 8, 48.	3.5	69
6	Blockade of IL-18 signaling diminished neuropathic pain and enhanced the efficacy of morphine and buprenorphine. <i>Molecular and Cellular Neurosciences</i> , 2016, 71, 114-124.	2.2	65
7	Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 64, 68-78.	4.8	60
8	Direct and indirect pharmacological modulation of CCL2/CCR2 pathway results in attenuation of neuropathic pain – In vivo and in vitro evidence. <i>Journal of Neuroimmunology</i> , 2016, 297, 9-19.	2.3	54
9	The RS504393 Influences the Level of Nociceptive Factors and Enhances Opioid Analgesic Potency in Neuropathic Rats. <i>Journal of Neuroimmune Pharmacology</i> , 2017, 12, 402-419.	4.1	52
10	Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model. <i>Neuropharmacology</i> , 2016, 102, 80-91.	4.1	49
11	Involvement of Macrophage Inflammatory Protein-1 Family Members in the Development of Diabetic Neuropathy and Their Contribution to Effectiveness of Morphine. <i>Frontiers in Immunology</i> , 2018, 9, 494.	4.8	48
12	IL-1 receptor antagonist improves morphine and buprenorphine efficacy in a rat neuropathic pain model. <i>European Journal of Pharmacology</i> , 2015, 764, 240-248.	3.5	47
13	Chemokines CCL2 and CCL7, but not CCL12, play a significant role in the development of pain-related behavior and opioid-induced analgesia. <i>Cytokine</i> , 2019, 119, 202-213.	3.2	46
14	Comparison of the Expression Changes after Botulinum Toxin Type A and Minocycline Administration in Lipopolysaccharide-Stimulated Rat Microglial and Astroglial Cultures. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 141.	3.9	44
15	PD98059 Influences Immune Factors and Enhances Opioid Analgesia in Model of Neuropathy. <i>PLoS ONE</i> , 2015, 10, e0138583.	2.5	44
16	Pharmacological Inhibition of Indoleamine 2,3-Dioxygenase-2 and Kynurenine 3-Monooxygenase, Enzymes of the Kynurenine Pathway, Significantly Diminishes Neuropathic Pain in a Rat Model. <i>Frontiers in Pharmacology</i> , 2018, 9, 724.	3.5	41
17	Microglial Inhibition Influences XCL1/XCR1 Expression and Causes Analgesic Effects in a Mouse Model of Diabetic Neuropathy. <i>Anesthesiology</i> , 2016, 125, 573-589.	2.5	37
18	Pharmacological blockade of CXCR3 by (±)-NBI-74330 reduces neuropathic pain and enhances opioid effectiveness - Evidence from in vivo and in vitro studies. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 3418-3437.	3.8	37

#	ARTICLE	IF	CITATIONS
19	Botulinum Toxin Type A "A Modulator of Spinal Neuron-Glia Interactions under Neuropathic Pain Conditions. <i>Toxins</i> , 2018, 10, 145.	3.4	35
20	Spinal CCL1/CCR8 signaling interplay as a potential therapeutic target " Evidence from a mouse diabetic neuropathy model. <i>International Immunopharmacology</i> , 2017, 52, 261-271.	3.8	31
21	Neuropathic Pain Dysregulates Gene Expression of the Forebrain Opioid and Dopamine Systems. <i>Neurotoxicity Research</i> , 2020, 37, 800-814.	2.7	29
22	Minocycline Enhances the Effectiveness of Nociceptin/Orphanin FQ during Neuropathic Pain. <i>BioMed Research International</i> , 2014, 2014, 1-12.	1.9	28
23	The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain. <i>Immunology</i> , 2020, 159, 413-428.	4.4	28
24	Pharmacological Blockade of Spinal CXCL3/CXCR2 Signaling by NVP CXCR2 20, a Selective CXCR2 Antagonist, Reduces Neuropathic Pain Following Peripheral Nerve Injury. <i>Frontiers in Immunology</i> , 2019, 10, 2198.	4.8	27
25	Treatment with a carbon monoxide-releasing molecule (CORM-2) inhibits neuropathic pain and enhances opioid effectiveness in rats. <i>Pharmacological Reports</i> , 2016, 68, 206-213.	3.3	25
26	Biphalin, a Dimeric Enkephalin, Alleviates LPS-Induced Activation in Rat Primary Microglial Cultures in Opioid Receptor-Dependent and Receptor-Independent Manners. <i>Neural Plasticity</i> , 2017, 2017, 1-19.	2.2	24
27	Bidirectional Action of Cenicriviroc, a CCR2/CCR5 Antagonist, Results in Alleviation of Pain-Related Behaviors and Potentiation of Opioid Analgesia in Rats With Peripheral Neuropathy. <i>Frontiers in Immunology</i> , 2020, 11, 615327.	4.8	17
28	Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain. <i>Neuropharmacology</i> , 2020, 178, 108232.	4.1	14
29	Comparison of the Effects of Chemokine Receptors CXCR2 and CXCR3 Pharmacological Modulation in Neuropathic Pain Model "In Vivo and In Vitro Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11074.	4.1	13
30	Zaprinast diminished pain and enhanced opioid analgesia in a rat neuropathic pain model. <i>European Journal of Pharmacology</i> , 2018, 839, 21-32.	3.5	12
31	Novel bifunctional hybrid compounds designed to enhance the effects of opioids and antagonize the pronociceptive effects of nonopioid peptides as potent analgesics in a rat model of neuropathic pain. <i>Pain</i> , 2021, 162, 432-445.	4.2	9
32	Metamizole relieves pain by influencing cytokine levels in dorsal root ganglia in a rat model of neuropathic pain. <i>Pharmacological Reports</i> , 2020, 72, 1310-1322.	3.3	8
33	Bifunctional Opioid/Melanocortin Peptidomimetics for Use in Neuropathic Pain: Variation in the Type and Length of the Linker Connecting the Two Pharmacophores. <i>International Journal of Molecular Sciences</i> , 2022, 23, 674.	4.1	5
34	Dataset of (Å±)-NBI-74330 (CXCR3 antagonist) influence on chemokines under neuropathic pain. <i>Data in Brief</i> , 2018, 21, 1145-1150.	1.0	2